Sanofi Rare Blood Disorders Home

Innovating to bring therapies to you and your patients

Our two extended half-life factor replacement therapies for people with hemophilia A and B were launched in 2014, becoming the first innovations in hemophilia management in almost 20 years, and we remain committed to the hemophilia community.
We launched the first and only FDA approved treatment for acquired thrombotic thrombocytopenic purpura (aTTP).
We pioneered the first and only FDA approved treatment for cold agglutinin disease (CAD).

Learn more about our therapies for patients living with rare blood disorders

This site is intended for U.S. residents only.

© 2022 Genzyme Corporation. All rights reserved.

Sanofi is a registered trademark of Sanofi or an affiliate.
All other trademarks are the property of their respective owners.

MAT-US-2107338 v3.0 09/2022